Literature DB >> 8494128

The effect of cardiopulmonary bypass on cholinesterase activity.

E S Shearer1, G N Russell.   

Abstract

Cholinesterase activity was determined in 18 patients who had undergone either hypothermic (n = 9) or normothermic (n = 9) cardiopulmonary bypass. The anaesthetic technique was standardised to avoid agents known to affect cholinesterase. Activity was determined in blood samples taken before the induction of anaesthesia, during cardiopulmonary bypass and for at least 7 days postoperatively. In six patients cholinesterase activity was also measured at 6 weeks postoperatively. All the patients were of normal cholinesterase genotype. In both groups cholinesterase activity fell by approximately 60% coinciding with the start of cardiopulmonary bypass, from a mean of 5976 to 2636 IU.l-1 in the hypothermic group, and from 5901 to 2615 IU.l-1 in the normothermic group (p < 0.001 in both instances) (normal range 4300-10,500 IU.l-1). Cholinesterase activity remained at this reduced level for at least 7 days postoperatively. By 6 weeks, activity had returned to within 7% of pre-induction values. There were no differences in cholinesterase activity between the hypothermic and normothermic groups at any of the sampling times.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8494128     DOI: 10.1111/j.1365-2044.1993.tb06945.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  3 in total

Review 1.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

2.  Is succinylcholine appropriate or obsolete in the intensive care unit?

Authors:  L H Booij
Journal:  Crit Care       Date:  2001-08-31       Impact factor: 9.097

3.  Prolonged neuromuscular block associated with cholinesterase deficiency.

Authors:  Chao Zhang; Hui Cao; Zhi Gang Wan; Jie Wang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.